Preparation and in vitro evaluation of self-assembling peptide hydrogel loaded with doxorubicin

doi:10.3969/j.issn.2095-4344.3114

Abstract

Abstract: BACKGROUND: Chemotherapy is an important method for treating osteosarcoma, but traditional small molecule therapy is not ideal for clinical efficacy and has serious adverse reactions. Therefore, it is necessary to develop a new method for osteosarcoma, which can anti-tumor at low doses and reduce adverse reactions.
OBJECTIVE: To construct a self-assembling peptide hydrogel (SAPH) loaded with doxorubicin (DOX) and analyze its drug release performance and biocompatibility in vitro.
METHODS: DOX was introduced into SAPH composed of FEFEFKFK (F, phenylalanine; E, glutamic acid; K, lysine), prepared to contain 20, 30, and 40 g/L DOX-SAPH of FEFEFKFK; the DOX mass concentration in this system was 2 g/L. Three kinds of DOX-SAPH were placed in PBS, and the amount of DOX released was regularly detected. Three DOX-SAPH extracts were co-cultured with rabbit bone marrow mesenchymal stem cells, and the cell survival rate was detected by CCK-8 method. The DOX solution containing different concentrations of DOX and the DOX-SAPH extract (containing FEFEFKFK 30 g/L) were co-cultured with MG63 human osteosarcoma cells, and the cell survival rate was detected by CCK-8 method.
RESULTS AND CONCLUSION: (1) With the increase of the concentration of FEFEFKFK in the hydrogel, the sustained release effect of DOX-SAPH was enhanced. The cumulative drug release rate of DOX-SAPH at 20, 30, and 40 g/L at the 168th hour in vitro was 88%, 83%, and 80%. (2) The cells in 20 g/L DOX-SAPH extract group proliferated faster than 30 and 40 g/L DOX-SAPH extract group at 1, 3, and 5 days in vitro (P < 0.05), in which the 40 g/L DOX-SAPH extract group had certain cytotoxicity on the first day. (3) DOX solution and DOX-SAPH extract showed concentration-dependent inhibition of MG63 cell proliferation, when the concentration of DOX in the DOX solution and the DOX-SAPH extract was lower than 12.5 mg/L, there was no significant difference in the toxicity of the two to MG63 cells (P > 0.05). When the concentration of DOX was higher than 12.5 mg/L, the cell toxicity of the DOX solution was greater than that of DOX-SAPH extract (P < 0.05). (4) The results show that DOX-SAPH has a good drug slow-release effect, which can inhibit the growth of MG63 osteosarcoma cells.

Key words: bone, materials, hydrogel, tumor, doxorubicin, in vitro evaluation, osteosarcoma, tissue engineering

CLC Number:

Zhang Xin, Lu Ying, Yao Qingqiang, Zhu Yishen. Preparation and in vitro evaluation of self-assembling peptide hydrogel loaded with doxorubicin[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(16): 2488-2493.

Figures/Tables 7

References

[1] MISAGHI A, GOLDIN A, AWAD M, et al. Osteosarcoma: a comprehensive review. Sicot J. 2018;4(12):1-8.
[2] MA H, HE C, CHENG Y, et al. Localized Co-delivery of Doxorubicin, Cisplatin, and Methotrexate by Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment. ACS Appl Mater Interfaces. 2015;7(49): 27040-27048.
[3] 牛晓辉.骨肉瘤治疗的历史、现状和未来[J].骨科临床与研究杂志,2019, 4(5):257-260.
[4] DAHLIN DC, COVENTRY MB. Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am. 1967;49(1):101-110.
[5] MARCOVE RC, MIKE V, HAJEK JV, et al. Osteogenic sarcoma under the age of Twenty-one: review of one hundred and forty-five operative cases. J Bone Joint Surg Am. 1970;52(3):411-423.
[6] GIANFERANTE DM, MIRABELLO L, SAVAGE SA. Germline and somatic genetics of osteosarcoma-connecting aetiology biology and therapy. Nat Rev Endocrinol. 2017;13(8):480-491.
[7] HARRISON DJ, GELLER DS, GILL JD, et al. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer. 2017;18(1):39-50.
[8] ZHANG B, SHAN Y, CHEN K. A facile approach to fabricate of photothermal functional Fe3O4@CuS microspheres. Mater Chem Phys. 2017;193:82-88.
[9] HATTINGER CM, FANELLI M, TAVANTI E, et al. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Dr. 2015;20(3):495-514.
[10] SMORENBURG CH, DE GROOT SM, VAN LEEUWEN-STOK AE, et al. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann oncol. 2014;25(3):599-605.
[11] ALHOWAIL AH, BLOEMER J, MAJRASHI M, et al. Doxorubicin-induced neurotoxicity is associated with acute alterations in synaptic plasticity, apoptosis, and lipid peroxidation. Toxicol Mech Method. 2019;29(6): 457-466.
[12] VEJPONGSA P, YEH ETH. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938-945.
[13] HAGHIRALSADAT F, AMOABEDINY G, SHEIKHHA MH, et al. New liposomal doxorubicin nanoformulation for osteosarcoma: Drug release kinetic study based on thermo and pH sensitivity. Chem Biol Drug Des. 2017;90(3): 368-379.
[14] JONKER AM, LöWIK DWPM , VAN HEST JCM. Peptide- and Protein-Based Hydrogels. Chem Mater. 2012;24(5):759-773.
[15] TAO H, WU Y, LI H, et al. BMP7-Based Functionalized Self-Assembling Peptides for Nucleus Pulposus Tissue Engineering. ACS Appl Mater Inter. 2015;7(31):17076-17087.
[16] SARKAR B, NGUYEN PK, GAO W, et al. Angiogenic Self-Assembling Peptide Scaffolds for Functional Tissue Regeneration. Biomacromolecules. 2018; 19(9):3597-3611.
[17] KARAVASILI C, ANDREADIS DA, KATSAMENIS OL, et al. Synergistic Antitumor Potency of a Self-Assembling Peptide Hydrogel for the Local Co-delivery of Doxorubicin and Curcumin in the Treatment of Head and Neck Cancer. Mol Pharmaceutic. 2019;16(6):2326-2341.
[18] PHIPPS MC, MONTE F, MEHTA M, et al. Intraosseous Delivery of Bone Morphogenic Protein-2 Using a Self-Assembling Peptide Hydrogel. Biomacromolecules. 2016;17(7):2329-2336.
[19] KARAVASILI C, KOMNENOU A, KATSAMENIS OL, et al. Self-Assembling Peptide Nanofiber Hydrogels for Controlled Ocular Delivery of Timolol Maleate. ACS Biomater Sci Eng. 2017;3(12):3386-3394.
[20] DAO HM, CHEN J, TUCKER BS, et al. Hemopressin-Based pH-Sensitive Hydrogel: A Potential Bioactive Platform for Drug Delivery. ACS Biomater Sci Eng. 2018;4(7):2435-2442.
[21] WANG Y, CUI M, JIAO M, et al. Antifouling and ultrasensitive biosensing interface based on self-assembled peptide and aptamer on macroporous gold for electrochemical detection of immunoglobulin E in serum. Anal Bioanal Chem. 2018;410(23):5871-5878.
[22] LOWIK DW, LEUNISSEN EH, VAN DEN HEUVEL M, et al. Stimulus responsive peptide based materials. Chem Soc Rev. 2010;39(9):3394-3412.
[23] CUI M, WANG Y, JIAO M, et al. Mixed Self-Assembled Aptamer and Newly Designed Zwitterionic Peptide as Antifouling Biosensing Interface for Electrochemical Detection of alpha-Fetoprotein. ACS Sens. 2017;2(4): 490-494.
[24] LI L, LI JY, GUO JM, et al. 3D Molecularly Functionalized Cell-Free Biomimetic Scaffolds for Osteochondral Regeneration. Adv Funct Mater. 2018;29(6): 1807356.1-1807356.12.
[25] FREEMAN R, BOEKHOVEN J, DICKERSON MB, et al. Biopolymers and supramolecular polymers as biomaterials for biomedicals for biomedical applications. MRS Bull. 2015;40(12):1089-1101.
[26] SENAPATI S, MAHANTA AK, KUMAR S, et al. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Tar. 2018; 3(1):7.
[27] KARAVASILI C, PANTERIS E, VIZIRIANAKIS IS, et al. Chemotherapeutic Delivery from a Self-Assembling Peptide Nanofiber Hydrogel for the Management of Glioblastoma. Pharm Res. 2018;35(8):166.
[28] XU X, CHEN C, CHEN J. Molecular self-assembly of peptide. SCIENTIA SINICA Chimica. 2011;41(2):221-238.
[29] TANG C, MILLER AF, SAIANI A. Peptide hydrogels as mucoadhesives for local drug delivery. Int J Pharm. 2014;465(1-2):427-435.
[30] BOOTHROYD S, SAIANI A, MILLER AF. Controlling network topology and mechanical properties of co-assembling peptide hydrogels. Biopolymers. 2014;101(6):669-680.
[31] WAN S, BORLAND S, RICHARDSON SM, et al. Self-assembling peptide hydrogel for intervertebral disc tissue engineering. Acta Biomater. 2016;46:29-40.
[32] CASTILLO DIAZ LA, SAIANI A, GOUGH JE, et al. Human osteoblasts within soft peptide hydrogels promote mineralisation in vitro. J Tissue Eng. 2014;5:1-12.
[33] QI YQ, MIN H, MUJEEB A, et al. Injectable Hexapeptide Hydrogel for Localized Chemotherapy Prevents Breast Cancer Recurrence. ACS Appl Mater Inter. 2018;10(8):6972-6981.
[34] YOON SJ, MOON YJ, CHUN HJ, et al. Doxorubicin•Hydrochloride/Cisplatin-Loaded Hydrogel/Nanosized (2-Hydroxypropyl)-Beta-Cyclodextrin Local Drug-Delivery System for Osteosarcoma Treatment In Vivo. Nanomaterials. 2019;9(12):1652.
[35] GAO L, SUN Q, WANG Y, et al. Injectable poly(ethylene glycol) hydrogels for sustained doxorubicin release. Polym Advan Technol. 2017;28(1):35-40.
[36] YANG Z, YU S, LI D, et al. The effect of PLGA-based hydrogel scaffold for improving the drug maximum-tolerated dose for in situ osteosarcoma treatment. Colloids surf B Biointerfaces. 2018;172:387-394.
[37] CINAR G, OZDEMIR A, HAMSICI S, et al. Local delivery of doxorubicin through supramolecular peptide amphiphile nanofiber gels. Biomater Sci. 2016;5(1):67-76.
[38] YOO Y, YOON SJ, KIM SY, et al. A local drug delivery system based on visible light-cured glycol chitosan and doxorubicin•hydrochloride for thyroid cancer treatment in vitro and in vivo. Drug Deliv. 2018;25(1):1664-1671.
[39] DAS G, NICASTRI A, COLUCCIO ML, et al. FT-IR, Raman, RRS measurements and DFT calculation for doxorubicin. Microsc Res Techniq. 2010;73(10): 991-995.
[40] MUJEED A, MILLER AF, SAIANI A, et al. Self-assembled octapeptide scaffolds for in vitro chondrocyte culture. Acta Biomater. 2013;9(1):4609-4617.